Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares ...

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, ...

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a mini-rally that extended into Friday; the company's share price added nearly 5% ...

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

For Immediate ReleaseChicago, IL – May 10, 2023 – Zacks Equity Research shares Novo Nordisk A/S NVO as the Bull of the Day and Nutrien NTR as the Bear of the Day. In addition, Zacks Equity ...

Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-44.9% vs. -6.9%). The company's failure to meet the weight-loss target with CagriSema ...